Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-SARTATE PET Imaging in Neuroendocrine Tumors (CL01)
NCT04440956Phase 1Completed
- Sponsor
- Clarity Pharmaceuticals
- Start
- May 2015
- Primary completion
- Feb 2016
- Modality
- Peptide-Drug Conjugates
01
Overview
Phase 1, open-label, single-arm trial of Cu-64 sartate in neuroendocrine tumors (NETs), sponsored by Clarity Pharmaceuticals. Primary endpoints: Incidence of adverse events related to 64Cu-SARTATE at 1 week, Percentage of injected 64Cu-SARTATE dose found in organs of interest at 24 hours and 1 more. Started May 2015; status: completed.
02
Drugs
Cu-64 sartate
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT04440956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440956.